Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients
Open Access
- 2 February 2022
- journal article
- research article
- Published by S. Karger AG in Blood Purification
- Vol. 51 (10) , 875-878
Abstract
Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces risk of disease progression and hospitalization in high-risk subjects but no clear data on end-stage renal disease are available. We report 2 cases of Bamlanivimab/Etesevimab administration to two not hospitalized chronic hemodialysis patients with SARS-CoV2 infection. Since they are large molecules (human immunoglobulin G1) with molecular weight of 146,000 Da, administration was conducted during the second hour of the dialysis session with no adverse reaction. Conclusions: Intradialytic administration of Bamlanivimab/Etesevimab could be considered safe and may allow adequate clinical observation time without hospital-stay prolongation.Keywords
This publication has 5 references indexed in Scilit:
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- COVID-19 in dialysis patients: outlasting and outsmarting a pandemicKidney International, 2020
- Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, ChinaJournal of the American Society of Nephrology, 2020
- COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release SyndromeImmunity, 2020